Jump to content

ChromaDex

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Doprendek (talk | contribs) at 17:21, 17 November 2016 (added Category:1999 establishments in California using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

ChromaDex, Inc
Company typePublic
OTCQX:CDXC
IndustryPharmaceuticals, Natural products, Ingredients
Founded1999
HeadquartersIrvine, California, United States
Key people
Frank Jaksch
(Co-Founder, CEO)
ProductspTeroPure, NIAGEN (Nicotinamide Riboside), PURENERGY, ProC3G
WebsiteChromaDex.com

ChromaDex is a publicly traded natural products company based in Irvine, California. The company is most well known for its industry standard phytochemical testing laboratories and catalogue. In cooperation with the University of Mississippi, the company is currently exploring the effects of pterostiibene on humans.[1]

ChromaDex has licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound trademarked as pTeroPure via the company's BluScience product line.[2]

In 2010, ChromaDex won the North American Frost & Sullivan Award for Most Promising Ingredient of the Year for pTeroPure pterostilbene.[3]

In 2016, ChromaDex achieved GRAS status for its patented nicotinamide riboside product, NIAGEN, which allows it to be marketed in the food and beverage industries.[4] ChromaDex also initiated a 2nd human clinical trial on NIAGEN, to examine the benefits if taken daily for eight consecutive weeks.[5] In addition, ChromaDex was named as part of the OTCQX Best 50.[6]

American billionaire and pharmaceutical entrepreneur Phillip Frost owns approximately 19% of ChromaDex.[7][8]

Early history

ChromaDex was founded in 1999. According to a Standard & Poor's research report, the company was created "in response to growing demand for natural product reference standards, materials and services. It has worked to establish itself as an industry leader in nutraceutical and botanical certification, and even publishes its own manual outlining specifications for phytochemicals." On July 14, 2008 ChromaDex merged with CDI Acquisition, a subsidiary of Cody Resources Inc. On July 29, 2008 the company completed a private placement agreement, which yielded gross proceeds of $4.67 million.[9]

Later in 2008, ChromaDex (OTCQX: CDXC) became a publicly traded company. Shares of ChromaDex are traded on the OTC Markets QX Marketplace. As of April 2015, there were 108 million shares outstanding.[10]

ChromaDex catalogue

The ChromaDex catalogue "provides phytochemical reference standards, botanical reference materials and research grade materials for the natural products industry." The company sells over 3,000 phytochemicals and 470 botanical reference materials in its catalogue. The company's products reach a wide range of markets including food & beverage, pharmaceutical, cosmeceutical, research organizations and governmental groups.

pTeroPure

ChromaDex received exclusive worldwide patent rights for its pTeroPure pterostilbene product based on the technology licensed from the University of Mississippi and the USDA. Pterostilbene belongs to a class of compounds called phytoalexins, which are antimicrobial substances synthesized de novo by plants that accumulate rapidly at areas of incompatible pathogen infection.

Pterostilbene and resveratrol have similar pharmacologic properties. However pterostilbene has exhibited advantages over resveratrol including superior biological activity, better oral bioavailability, and a slower metabolizing time, which provides more time for the compound's antioxidant activities to act.[11][12][13]

According to the USDA, "pterostilbene is one of many aromatic hydrocarbons called stilbenes." ChromaDex's pTeroPure is an identical form of trans-pterostilbene.

The University of California, Irvine, is currently studying pTeroPure for its efficacy as a treatment for melanomas and other skin cancers when used in a skincare product.[14]

Niagen & Nicotinamide riboside technology

On July 13, 2011, Cornell University announced it granted ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR). NR, a vitamin found in milk, is a more potent version of niacin (vitamin B3). Like niacin, NR is a precursor to nicotinamide adenine dinucleotide (NAD), which is elevated by a calorie restricted diet. Increasing cellular NAD has demonstrated cell-protective and positive metabolic effects. In laboratory tests, "NR has shown promise for improving cardiovascular health, glucose levels and cognitive function and has demonstrated evidence of anti-ageing effects."[15][16]

ChromaDex markets and sells nicotinamide riboside as an ingredient under the brand name Niagen.

In 2015, ChromaDex announced the results of its first clinical study, stating "Niagen Nicotinamide Riboside Effectively Increases the Co-enzyme NAD+ and is Safe".[17]

In 2016, ChromaDex initiated a second human clinical trial on Niagen, a randomized, double-blind, placebo controlled parallel study in 140 healthy adults ranging in age from 40-60, to examine the benefits if taken daily for eight consecutive weeks[5]

Contract research services & capabilities

ChromaDex also offers contract research services that help customers source raw materials, identify new compounds and develop processes for large scale manufacturing. The company also has a number of analytical capabilities including gas chromatography, mass spectrometry, Near-infrared spectroscopy, and high performance liquid chromatography.[10]

See also

References

  1. ^ Standard & Poor's (2013-10-05). "ChromaDex: Standard & Poor's Factual Report". Standard & Poors. p. 10. Retrieved 2013-10-10.
  2. ^ Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp". The Daily Mississippian. Retrieved 2012-05-25.
  3. ^ "Frost & Sullivan Recognizes ChromaDex for the Unique Potential Its Commercially Available Product Offers in the Human Nutrition Industry". Yahoo Finance. 5-3-2011. Retrieved 2012-05-25. {{cite web}}: Check date values in: |date= (help)
  4. ^ "ChromaDex Lead Ingredient NIAGEN® Nicotinamide Riboside Achieves GRAS Status". TheStreet. Retrieved 2016-03-22.
  5. ^ a b Inc., ChromaDex,. "ChromaDex Initiates Second Human Clinical Study on NIAGEN® -The World's First and Only Commercially Available Form of Nicotinamide Riboside (NR)". GlobeNewswire News Room. Retrieved 2016-03-22. {{cite web}}: |last= has generic name (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
  6. ^ "OTC Markets Group Announces the 2016 OTCQX Best 50 - OTCMarkets.com". www.otcmarkets.com. Retrieved 2016-03-21.
  7. ^ Gould, David (5-3-2011). "Billionaire Phillip Frost: A Case Study In Synergy". TREFIS. Retrieved 2012-05-29. {{cite web}}: Check date values in: |date= (help)
  8. ^ "ChromaDex Corp. Names Consumer Products Veteran Jeffrey Himmel CEO". 2012-1-23. Retrieved 2012-05-29. {{cite web}}: Check date values in: |date= (help)
  9. ^ "Functional Ingredients". 5-10-2009. Retrieved 2012-05-29. {{cite web}}: Check date values in: |date= (help)
  10. ^ a b "OTC Markets Stock Profile CDXC". OTC Markets. Retrieved 2016-03-21.
  11. ^ IM Kapetanovic; et al. (November 2010). "Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats". Cancer Chemother Pharmacol. 68 (3): 593–601. doi:10.1007/s00280-010-1525-4. PMC 3090701. PMID 21116625.
  12. ^ CM Remsberg; et al. (February 2008). "Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity". Phytother Res. 22 (2): 169–79. doi:10.1002/ptr.2277. PMID 17726731.
  13. ^ P Ferrer; et al. (January 2005). "Association between Pterostilbene and Quercetin Inhibits Metastatic Activity of B16 Melanoma". Neoplasia. 7 (1): 37–47. doi:10.1593/neo.04337. PMC 1490314. PMID 15736313.
  14. ^ "Best of 2011 Ingredient Supplier: ChromaDex". Nutritional Outlook. Retrieved 2012-05-29.
  15. ^ "Got nicotinamide riboside?". Life Extension. 2007-05-04. Retrieved 2012-05-29.
  16. ^ Belenky P; Bogan KL; Brenner C (2007). "NAD+ metabolism in health and disease" (PDF). Trends Biochem. Sci. 32 (1): 12–9. doi:10.1016/j.tibs.2006.11.006. PMID 17161604. Retrieved 2007-12-23.
  17. ^ Inc., ChromaDex,. "Results from First Human Clinical Study Demonstrate ChromaDex's NIAGEN(R) Nicotinamide Riboside Effectively Increases the Co-enzyme NAD+ and is Safe". GlobeNewswire News Room. Retrieved 2016-03-21. {{cite web}}: |last= has generic name (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=ChromaDex&oldid=750067712"